Hot Investor Mandate 1: China PE Firm Invests in Oncology, Cardiovascular & Psychiatry Therapeutics

19 Jan

A private equity firm based in Beijing, China with total asset under management of over US$1 billion seeks early to growth stage opportunities that are suitable for the China market and invests across several industry sectors including healthcare. The firm also partners with public enterprises in China on M&A and licensing opportunities. Typical equity investments range from 10 million to 4 billion RMB (US$1.5 to 600 million). The firm is now looking for opportunities in China, Israel, the US, and Canada.

Within healthcare, the firm is interested in therapeutic products in cardiovascular, psychiatry, and oncology. The firm prefers clinical stage projects from phase I to IIa trials, and is opportunistic in terms of modality. The firm is also interested in medical devices in ophthalmology and orthopedics that have at least obtained prototype and clinical validation.

The firm is looking for products with a China angle.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: